Advertisement

Gynecologic Cancer

  • Sevilay Altintas
  • Dirk L. A. L. Schrijvers
Chapter

Abstract

Gynecologic tumors constitute an important part of cancer in women. There have been improvements in outcomes after surgery, chemotherapy, and radiation therapy; however, patients do experience significant treatment-related side effects.

Besides the classical cytotoxic agents and hormonal agents, used for many years, the development of newer molecular targeted and immunotherapeutic agents is currently an exciting area of interest in the care of patients with gynecologic malignancies.

Challenges are careful selection of patients for optimizing the combination of treatment modalities and drugs in order to obtain optimal efficacy. The latter depends on several factors: (1) the drug must be active as single agent against the particular tumor; (2) the drugs should have different mechanisms of action to minimize emergence of drug resistance; (3) the drugs should have a biochemical basis of at least additive and preferably synergistic effects; (4) the drugs chosen should have a different spectrum of toxicity so they can be used for maximum cell kill at full doses; and (5) the drugs chosen should be administered intermittently so that cell kill is enhanced and prolonged immunosuppression is minimized. This chapter gives an overview of the currently used treatment modalities in gynecologic cancer, their side effects, and their management.

Keywords

Gynecologic cancer Ovarian cancer Endometrial cancer Cervical cancer Vulvar cancer Gestational trophoblastic neoplasia Chemotherapy Hormonal therapy Targeted therapy Side effects 

References

  1. 1.
    International Agency for Research on Cancer. Eucan Fact Sheets. http://eco.iarc.fr/eucan/CancerSearch.aspx (consulted 12/02/2018).
  2. 2.
    Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. In:WHO classification of tumours, IARC WHO Classification of Tumours, vol. 6. 4th ed; 2014.Google Scholar
  3. 3.
    Brierley J, Gospodarowisz M, Wittekind C, editors. TNM classification of malignant tumours. 8th ed. Oxford: Wiley; 2017.Google Scholar
  4. 4.
    National Cancer Comprehensive Network. NCCN clinical practice guidelines in oncology. Ovarian cancer. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (consulted 12/02/2018).
  5. 5.
    van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.  https://doi.org/10.1056/NEJMoa1708618.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–82.  https://doi.org/10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009;27(28):4642–8.  https://doi.org/10.1200/JCO.2009.21.9691. Epub 2009 Aug 24.CrossRefPubMedGoogle Scholar
  8. 8.
    Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114(2):195–8.  https://doi.org/10.1016/j.ygyno.2009.04.012. Epub 2009 May 17.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5.  https://doi.org/10.1245/s10434-014-4157-9. Epub 2014 Nov 13.CrossRefPubMedGoogle Scholar
  10. 10.
    Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol. 2016;27(12):2236–41.  https://doi.org/10.1093/annonc/mdw418. Epub 2016 Oct 26.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107–14.  https://doi.org/10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.  https://doi.org/10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.  https://doi.org/10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45.  https://doi.org/10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–6.  https://doi.org/10.1016/j.ygyno.2015.08.004. Epub 2015 Aug 10.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.  https://doi.org/10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan R, Parmar MKB, ICON6 Collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–74.  https://doi.org/10.1016/S0140-6736(15)01167-8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    European Medicinal agency. Assessment Report Zemfirza. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2016/12/WC500218922.pdf (consulted 18/02/2018).
  19. 19.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.  https://doi.org/10.1056/NEJMoa1105535.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P, SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84.  https://doi.org/10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87–97.  https://doi.org/10.1016/S1470-2045(14)71135-0. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. Lancet Oncol. 2015 Feb;16(2):e55.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14.  https://doi.org/10.1016/S1470-2045(14)70391-2.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154–64. Epub 2016 Oct 7.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O’Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–75.  https://doi.org/10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C, Weil SC, Bamias A, Fujiwara K, Ochiai K, Poole C, Gorbunova V, Wang W, O’Shannessy D, Herzog TJ. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016;34:2271–8.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Tagawa T, Morgan R, Yen Y, Mortimer J. Ovarian cancer: opportunity for targeted therapy. J Oncol. 2012;2012:682480.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Gynecologic Oncology Group, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group Study. Gynecol Oncol. 2008;108(3):493–9.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2008;110(2):140–5.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11(15):5539–48.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer. 2005;15(5):785–92.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):569–74.  https://doi.org/10.1016/j.ygyno.2011.10.022.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broët S. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One. 2007 Nov 7;2(11):e1138.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Turner TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, Arend RC. Ovarian cancer and the immune system – the role of targeted therapies. Gynecol Oncol. 2016;142:349–56.  https://doi.org/10.1016/j.ygyno.2016.05.007.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, Valabrega G. Adoptive immunotherapy against ovarian cancer. J Ovarian Res. 2016;9(1):30.  https://doi.org/10.1186/s13048-016-0236-9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Weiss L, Huemer F, Mlineritsch B, Greil R. Immune checkpoint blockade in ovarian cancer. Memo. 2016;9:82–4.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA, Shi JG, Liu X, Newton RC, Zhao Y, Maleski J, Leopold L, Schilder RJ. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol Oncol. 2017;146(3):484–90.  https://doi.org/10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013;31(12):1554–61.  https://doi.org/10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017;116(4):455–63.  https://doi.org/10.1038/bjc.2016.435. Epub 2017 Jan 24.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C. ESMO Guidelines Working Group. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii20–6.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Uçar MG, Çakir T, Ilhan TT, Karabagli P, Çelik Ç. Primary ovarian malignant mixed mullerian tumour: a case report and brief review of literature. J Clin Diagn Res. 2016;10(3):QD04–6.  https://doi.org/10.7860/JCDR/2016/18127.7457.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    National Cancer Comprehensive Network. NCCN Clinical practice guidelines in oncology. Uterine Cancer. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (consulted 15/02/2018).
  42. 42.
    Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi33–8.  https://doi.org/10.1093/annonc/mdt353.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL, PORTEC Study Group. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:1114–26.  https://doi.org/10.1016/S1470-2045(16)30120-6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist. 2016;21(10):1250–9. Epub 2016 Jul 13.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Santaballa A, Matías-Guiu X, Redondo A, Carballo N, Gil M, Gómez C, Gorostidi M, Gutierrez M, Gónzalez-Martín A. SEOM clinical guidelines for endometrial cancer (2017). Clin Transl Oncol. 2018;20(1):29–37.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1966;14:357–61.CrossRefGoogle Scholar
  47. 47.
    Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose–response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736–44.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364–7.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W, Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14(4):650–8.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65.  https://doi.org/10.1200/JCO.2010.32.6397.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278–85.  https://doi.org/10.1200/JCO.2010.34.1578.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319–25.  https://doi.org/10.1200/JCO.2007.15.8808.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–9.  https://doi.org/10.1002/cncr.25515.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Simpkins F, Drake R, Escobar PF, Nutter B, Rasool N, Rose PG. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecol Oncol. 2015;136(2):240–5.  https://doi.org/10.1016/j.ygyno.2014.12.004.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(1):22–7.  https://doi.org/10.1016/j.ygyno.2012.12.022.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–6.  https://doi.org/10.1200/JCO.2014.58.3401.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15–20.  https://doi.org/10.1016/j.ygyno.2009.09.025. Epub 2009 Oct 18.CrossRefPubMedPubMedCentralGoogle Scholar

Cervical Cancer References

  1. 58.
    Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, ESMO Guidelines Working Group. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii27–32.PubMedPubMedCentralGoogle Scholar
  2. 59.
    National Cancer Comprehensive Network. NCCN Clinical practice guidelines in oncology. Cervical cancer. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf (consulted 14/07/2016).
  3. 60.
    Green JA, Kirwan JM, Tierney JF. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 61.
    Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22(15):3113–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 62.
    Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–55.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 63.
  7. 64.
    Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.  https://doi.org/10.1056/NEJMoa1309748.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 65.
    Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015;121(13):2156–63.  https://doi.org/10.1002/cncr.29337. Epub 2015 Apr 6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 66.
    Schefter T, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W Jr, Sause W, Gaffney D. Radiation Therapy Oncology Group (RTOG). RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014;88(1):101–5.  https://doi.org/10.1016/j.ijrobp.2013.10.022.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 67.
    Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase III open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28(22):3562–9.  https://doi.org/10.1200/JCO.2009.26.9571.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 68.
    Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116(2):163–7.  https://doi.org/10.1016/j.ygyno.2009.08.012.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 69.
    Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M, Hudson E, Reed N, Flubacher M, Jankowska P, Powell M, Dive C, West CM, Paul J. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16(15):1515–24.  https://doi.org/10.1016/S1470-2045(15)00220-X.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 70.
    Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, MacKay H. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol. 2013;130(2):269–74.  https://doi.org/10.1016/j.ygyno.2013.05.008.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 71.
    Nogueira-Rodrigues A, Moralez G, Grazziotin R, Carmo CC, Small IA, Alves FV, Mamede M, Erlich F, Viegas C, Triginelli SA, Ferreira CG. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;120(8):1187–93.  https://doi.org/10.1002/cncr.28471.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 72.
    Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(3):495–500.  https://doi.org/10.1016/j.ygyno.2011.05.040.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 73.
    Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121(2):303–8.  https://doi.org/10.1016/j.ygyno.2011.01.030.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 74.
    Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, Weber B, Guillemet C, Paraiso D, Pujade-Lauraine E. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol. 2009;113(1):16–20.  https://doi.org/10.1016/j.ygyno.2008.12.040.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 75.
    Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;127(3):456–61.  https://doi.org/10.1016/j.ygyno.2012.08.030.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 76.
    de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM. PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy ± cetuximab in cervical cancer patients. Clin Cancer Res. 2015;21(11):2530–7.  https://doi.org/10.1158/1078-0432.CCR-14-2368.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 77.
    Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K, Noda K. Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. Ann Oncol. 2014;25(5):1011–7.  https://doi.org/10.1093/annonc/mdu057.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 78.
    Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–41.  https://doi.org/10.1200/JCO.2017.74.5471.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 79.
    Moore DH, Koh WJ, McGuire WP, et al. Vulva. In: Hoskins WJ, Perez CA, Young RC, et al., editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 665–705.Google Scholar
  23. 80.
    Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol. 2006;60(3):227–41.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 81.
    Durrant KR, Mangioni C, Lacave AJ, George M, van der Burg ME, Guthrie D, et al. Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG). Gynecol Oncol. 1990;37(3):359–62.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 82.
    Wagenaar HC, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol. 2001;81(3):348–54.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 83.
    May T, Goldstein DP, Berkowitz RS. Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother Res Pract. 2011;2011:806256.  https://doi.org/10.1155/2011/806256.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 84.
    Goldstein DP. Gestational trophoblastic neoplasia in the 1990s. Yale J Biol Med. 1991;64:639–51.PubMedPubMedCentralGoogle Scholar
  28. 85.
    Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia; a progress report. J Reprod Med. 2002;47(6):445–50.PubMedGoogle Scholar
  29. 86.
    Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2005;97(2):618–23.PubMedCrossRefGoogle Scholar
  30. 87.
    Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, Akarca A, Marafioti T, Quezada SA, Sarwar N, Seckl MJ. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017;390(10110):2343–5.  https://doi.org/10.1016/S0140-6736(17)32894-5.CrossRefPubMedGoogle Scholar
  31. 88.
    Skeel RT. Handbook of cancer chemotherapy. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.Google Scholar
  32. 89.
    Chabner B, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.Google Scholar
  33. 90.
    Takimoto CH, Calvo E. Principles of oncologic pharmacotherapy. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, editors. Cancer management: a multidisciplinary approach. 11th ed. Lawrence: CMPMedica; 2008.Google Scholar
  34. 91.
    Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. Clin Oncol. 2010;28:3107–14.CrossRefGoogle Scholar
  35. 92.
    Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D’Incalci M, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011;123(3):553–6.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 93.
    Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch U, Tagliaferri M, Hannah AL, Garcia AA. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2017;147(2):276–82.  https://doi.org/10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 94.
    Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18(Suppl 5):v9–v15.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 95.
    Kauffman D, et al. Clinical consequences and management of antineoplastic agents. In: Parrillo JE, Masur H, editors. The critically ill immunosuppressed patient: diagnosis and management. Rockville: Aspen Press; 1986.Google Scholar
  39. 96.
    Stampler KM, Holtz DO, Dunton CJ. Reducing excessive toxicity in ovarian cancer treatment: a personalized approach. Future Oncol. 2011;7:789–98.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 97.
    Verplanke AJ, Herber RF, de Wit R, Veenhof CH. Comparison of renal function parameters in the assessment of cisplatin induced nephrotoxicity. Nephron. 1994;66(3):267–72.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 98.
    Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277–88. Epub 2016 Jul 22. Review.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 99.
    Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J. ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111–8.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 100.
    Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21(Suppl 5):v244–7.  https://doi.org/10.1093/annonc/mdq202. No abstract available.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 101.
    Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol. 2001;12(9):1195–203.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 102.
    Markman M, Kennedy A, Webster K. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17(4):1141.CrossRefPubMedGoogle Scholar
  46. 103.
    Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 104.
    Harano K, Terauchi F, Katsumata N, et al. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a First-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG 3016). Ann Oncol. 2014;25(1):251–7.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 105.
    Vergote I, Debruyne P, Kridelka F, et al. Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers: a study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecol Oncol. 2015;138(2):278–84.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 106.
    Katanyoo K, Tangjitgamol S, Chongthanakorn M, Tantivatana T, Manusirivithaya S, Rongsriyam K, et al. Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol. 2011;123(3):571–6.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 107.
    Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 108.
    Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 109.
    Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 110.
    Einstein MH, Parashar B, Sood B, Goldman N, Goldberg GL, Runowicz CD, et al. Long-term complications of concomitant chemoradiotherapy for locally advanced cervical cancer. Proc Am Soc Clin Oncol. 2002;21:abstr 2526.Google Scholar
  54. 111.
    Di Stefano M, Fagotti A, Ferrandina G, Francesco F, Daniela S, Giuseppe D, et al. Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications. Gynecol Oncol. 2005;99:S166–70.CrossRefGoogle Scholar
  55. 112.
    Bye A, Ose T, Kaasa S. Quality of life during pelvic radiotherapy. Acta Obstet Gynecol Scand. 1995;74:147–52.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 113.
    Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol. 1996;14(6):1895–902.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 114.
    Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75(5):1141–50.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 115.
    Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–91.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 116.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901–5.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 117.
    Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472–8.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 118.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Use of low dose oral prednisone to prevent paclitaxel-induced myalgias and arthralgias. Gynecol Oncol. 1999;72(1):100.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 119.
    Savarese D, Boucher J, Corey B. Glutamine treatment of paclitaxel induced myalgias and arthralgias. J Clin Oncol. 1998;16:3918–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 120.
    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.CrossRefPubMedGoogle Scholar
  64. 121.
    Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18(1):106–15.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 122.
    Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654–66.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 123.
    Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer. 2006;16(Suppl 1):391–3.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 124.
    Sessa C, Marsoni S. Randomized single-agents trials in recurrent epithelial ovarian cancer. Int J Gynecol Cancer. 2005;15(Suppl 3):247–51.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 125.
    Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist. 2002;7(Suppl 5):29–35.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 126.
    O’Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP 3rd, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15(1):177–86.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 127.
    Ten Bokkel Huinink W, Lane SR, Ross GA, International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004;15(1):100–3.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 128.
    Armstrong D, O’Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 1998;3(1):4–10.PubMedPubMedCentralGoogle Scholar
  72. 129.
    Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001;83(2):257–62.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 130.
    Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9(1):33–42.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 131.
    O’Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst. 1996;88(12):817–24.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 132.
    Möbus V, Pfaff PN, Volm T, Kreienberg R, Kaubitzsch S. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. Anticancer Res. 2001;21(5):3551–6.PubMedPubMedCentralGoogle Scholar
  76. 133.
    Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 134.
    Hansen SW. Gemcitabine in the treatment of ovarian cancer. Int J Gynecol Cancer. 2001;11(Suppl 1):39–41.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 135.
    Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26–32.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 136.
    Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 2006;33(2 Suppl 6):S12–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 137.
    Abbruzzese JL. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol. 1996;23(5 Suppl 10):25–31.PubMedPubMedCentralGoogle Scholar
  81. 138.
    Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs. 1995;6(Suppl 6):61–2.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 139.
    Sauer-Heilborn A, Kath R, Schneider CP, Höffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol. 1999;125(11):637–40.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 140.
    Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6(2):153–61.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 141.
    Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18(1):85–91.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 142.
    Martin C, Lund B, Anderson H, Thatcher N. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs. 1996;7(3):351–7.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 143.
    Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis. 1999;33(3):555–62.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 144.
    Weinberg LE, Lurain JR, Singh DK, Schink JC. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol. 2011;121(2):285–9.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 145.
    Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16(2):405–10.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 146.
    Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 1998;70(2):267–71.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 147.
    Rose PG, Blessing JA, Van Le L, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1998;70(2):263–6.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 148.
    Fleming RA, Miller AA, Stewart CF. Etoposide: an update. Clin Pharm. 1989;8(4):274–93.PubMedPubMedCentralGoogle Scholar
  92. 149.
    De Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M. Hypersensitivity reactions to etoposide. A report of three cases and review of the literature. Am J Clin Oncol. 1994;17(5):387–9.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 150.
    Fleming GF, Brunetto VL. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159–66.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 151.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323–9.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 152.
    Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005;96(1):10–8.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 153.
    Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109–18.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 154.
    Gabizon A, Catane R, Uziely R, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–92.PubMedPubMedCentralGoogle Scholar
  98. 155.
    Alberts DS. Treatment of refractory and recurrent ovarian cancer. Semin Oncol. 1999;26(1 Suppl 1):8–14.PubMedPubMedCentralGoogle Scholar
  99. 156.
    Berri G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients with pegylated liposomal doxorubicin. Ann Oncol. 1998;9:711–6.CrossRefGoogle Scholar
  100. 157.
    Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol. 1998;70(1):70–4.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 158.
    Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191–214.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 159.
    Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80–4.PubMedCrossRefGoogle Scholar
  103. 160.
    Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer. 2011;11(2):73–81.PubMedCrossRefGoogle Scholar
  104. 161.
    Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol. 1998;70(2):272–4.PubMedCrossRefGoogle Scholar
  105. 162.
    Liu YL, Tsai SH, Chang FW, Yu MH. Ifosfamide-induced encephalopathy in patients with uterine sarcoma. Taiwan J Obstet Gynecol. 2010;49(1):77–80.PubMedCrossRefGoogle Scholar
  106. 163.
    Pearl ML, Inagami M, McCauley DL, Valea FA, Chalas E, Fischer M. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecologic sarcomas. Int J Gynecol Cancer. 2002;12(6):745–8.PubMedCrossRefGoogle Scholar
  107. 164.
    Kosmas C, Mylonakis N, Tsakonas G, Vorgias G, Karvounis N, Tsavaris N, et al. Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. Br J Cancer. 2009;101:1059–65.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 165.
    Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005;23(18):4137–45.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 166.
    Lissoni AA, Fei F, Rossi R, Fruscio R, Villa A, Zani G. Ifosfamide in the treatment of malignant epithelial ovarian tumors. Oncology. 2003;65(Suppl 2):59–62.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 167.
    Pelgrims J, De Vos F, Van den Brande J. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291–4.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 168.
    Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064–72.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 169.
    Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007;15(12):1341–7.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 170.
    Cantwell BM, Idle M, Millward MJ, Hall G, Lind MJ. Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion. Ann Oncol. 1990;1(3):232.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 171.
    Piccart MJ, Bertelsen K, James K. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699–708.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 172.
    Muntz HG, Goff BA, Fuller AF Jr. Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen. Eur J Gynaecol Oncol. 1990;11(4):263–8.PubMedPubMedCentralGoogle Scholar
  116. 173.
    Signorelli M, Chiappa V, Minig L, Fruscio R, Perego P, Caspani G, et al. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. Int J Gynecol Cancer. 2009;19(6):1142–6.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 174.
    Rochelle E, Curtis MA, Boice JD, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745–51.CrossRefGoogle Scholar
  118. 175.
    Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651–8.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 176.
    Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. Clin Oncol. 1994;12(4):701–6.CrossRefGoogle Scholar
  120. 177.
    Ginsberg SJ, Cornis RL. The pulmonary toxicity of neoplastic agents. Semin Oncol. 1982;9:34–7.PubMedPubMedCentralGoogle Scholar
  121. 178.
    White DA, Stover DE. Severe bleomycin induced pneumonitis. Clinical features and response to corticosteroids. Chest. 1984;86:723–8.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 179.
    O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–6.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 180.
    Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991–4008.PubMedCrossRefGoogle Scholar
  124. 181.
    Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29(7):825–31.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 182.
    Rustin GJS, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996;14(10):2769–73.PubMedCrossRefGoogle Scholar
  126. 183.
    Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703.PubMedCrossRefGoogle Scholar
  127. 184.
    De Miguel D, García-Suárez J, Martín Y, Gil-Fernández JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant. 2008;23(12):3762–6.PubMedCrossRefGoogle Scholar
  128. 185.
    Look KY, Blessing JA, Valea FA, McGehee R, Manetta A, Webster KD, et al. Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1997;67(3):255–8.PubMedCrossRefGoogle Scholar
  129. 186.
    Look KY, Muss HB, Blessing JA, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1995;18(1):19–22.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 187.
    De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10:1795–801.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 188.
    van Kuilenburg AB, Meinsma R, Zonnenberg BA, Zoetekouw L, Baas F, Matsuda K, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res. 2003;9:4363.PubMedPubMedCentralGoogle Scholar
  132. 189.
    Peterson DE, Bensadoun RJ, Roila F. ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):vi78–84.PubMedPubMedCentralGoogle Scholar
  133. 190.
    Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42(10):1484–90.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 191.
    Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol. 2009;20(11):1794–802.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 192.
    Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361–8.  https://doi.org/10.1016/j.ejca.2012.04.001.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 193.
    Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30(31):3841–7.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 194.
    Roque DM, Ratner ES, Silasi DA, et al. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: a retrospective review. Gynecol Oncol. 2015;137(3):392–400.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 195.
    Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(4):437–43.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 196.
    Markman M. Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin. Ther Clin Risk Manag. 2009;5(1):161–8.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 197.
    Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, et al. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125(1):54–8.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 198.
    Nagao S, Iwasa N, Kurosaki A, Nishikawa T, Ohishi R, Hasegawa K, et al. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study. Int J Gynecol Cancer. 2012;22(1):70–5.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 199.
    Helm CW, Randall-Whitis L, Martin RS, Metzinger DS, Gordinier ME, Parker LP, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007;105(1):90–6.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 200.
    Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135(12):1637–45.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 201.
    Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106(2):197–203.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 202.
    Garrett A, Quinn MA. Hormonal therapies and gynecologic cancers. Best Pract Res Clin Obstet Gynaecol. 2008;22:407–21.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 203.
    Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol. 2007;24:39–43.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 204.
    Fishman A, Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Kaplan AL, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med. 1996;41:393–6.PubMedPubMedCentralGoogle Scholar
  148. 205.
    Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004;66:112–7.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 206.
    Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007;18(Suppl 8):viii26–35.PubMedPubMedCentralGoogle Scholar
  150. 207.
    Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol. 2007;18(Suppl 8):viii36–44.PubMedPubMedCentralGoogle Scholar
  151. 208.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 209.
    Breast International Group (BIG) 1–98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–56.CrossRefGoogle Scholar
  153. 210.
    Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol. 2014;71(2):217.e1–217.e11.; quiz 227–8.  https://doi.org/10.1016/j.jaad.2014.04.013.CrossRefGoogle Scholar
  154. 211.
    Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11(5):465–75.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 212.
    Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. 2012;11(Suppl 1):S9–19.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 213.
    Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807–15.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 214.
    Li J, Zhou L, Chen X, Ba Y. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. Clin Transl Oncol. 2015;17(9):673–83.  https://doi.org/10.1007/s12094-015-1293-z.CrossRefPubMedPubMedCentralGoogle Scholar
  158. 215.
    Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer. 2012;48(7):974–81.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 216.
    Lheureux S, Bowering V, Karakasis K, Oza AM. Safety evaluation of olaparib for treating ovarian cancer. Expert Opin Drug Saf. 2015;14(8):1305–16.  https://doi.org/10.1517/14740338.2015.1045875.CrossRefPubMedPubMedCentralGoogle Scholar
  160. 217.
  161. 218.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical OncologyUniversity Hospital AntwerpAntwerpBelgium
  2. 2.Department of Medical OncologyZiekenhuisnetwerk Antwerpen (ZNA)AntwerpBelgium

Personalised recommendations